No products in the cart.
Pre-made Tesnatilimab benchmark antibody ( Whole mAb, anti-KLRK1 therapeutic antibody, Anti-CD314/D12S2489E/KLR/NKG2-D/NKG2D Antibody) for drug discovery and mechanism of action (MOA) research
Cat:GMP-Bios-ab-566
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Tesnatilimab biosimilar, Whole mAb, Anti-KLRK1 Antibody: Anti-CD314/D12S2489E/KLR/NKG2-D/NKG2D therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Tesnatilimab (formerly JNJ 4500) is being developed by Janssen Biotech, for the treatment of autoimmune diseases, including Crohn’s disease.
| Products Name (INN Index) | Pre-Made Tesnatilimab biosimilar, Whole mAb, Anti-KLRK1 Antibody: Anti-CD314/D12S2489E/KLR/NKG2-D/NKG2D therapeutic antibody |
|---|---|
| INN Name | Tesnatilimab |
| Target | KLRK1 |
| Format | Whole mAb |
| Derivation | NA |
| Species Reactivity | Human |
| CH1 Isotype | IgG4 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2019 |
| Year Recommended | 2020 |
| Companies | Janssen Research & Development |
| Conditions Approved | NA |
| Conditions Active | Crohn's disease |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | KLRK1 |
| Package |
Previous slide
Next slide
